Pimasertib (PIM) versus dacarbazine (DTIC) in patients (pts) with cutaneous NRAS melanoma: a controlled, open-label phase II trial with crossover

Authors:

Abstract
Background: The MEK/ERK pathway is activated in many tumors and important for melanoma transformation and progression. Clinical activity observed with the MEK1/2 inhibitor PIM in a phase 1 trial in pts with melanoma, a population with an unmet medical need, triggered this phase 2 trial.